Indian Journal of Urology Users online:3500  
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size
Year : 2020  |  Volume : 36  |  Issue : 4  |  Page : 276-281

Long-term follow-up and outcomes of percutaneous nephron-sparing surgery for upper tract urothelial carcinoma

Department of Urology, Birmingham Heartlands Hospital, University Hospitals of Birmingham, Birmingham, UK

Correspondence Address:
Piyush Bhargav Sarmah
Department of Urology, Birmingham Heartlands Hospital, University Hospitals of Birmingham, Birmingham
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/iju.IJU_93_20

Rights and Permissions

Introduction: Upper tract urothelial carcinoma (UTUC) is uncommon, accounting for 5%–10% of all urothelial carcinomas. Current standard of care for localized disease consists of radical nephroureterectomy (RNU) which leads to loss of half the patient's functioning nephrons. Percutaneous nephron-sparing surgery (PCNSS) is an alternative minimally-invasive approach in selected cases where nephron preservation is desired. The long-term outcomes of this procedure at a single center are described. Methods: All patients undergoing PCNSS, with the operation carried out by a single surgeon, were included. Equipment used was a standard 26Ch resectoscope through a 30Ch Amplatz sheath, with all patients receiving postoperative intrapelvic Mitomycin. Data for each patient were collected on patient age; tumor size at diagnosis; grade; stage; oncological recurrence; requirement for subsequent RNU; and overall survival. Primary outcomes were disease recurrence and overall mortality, and secondary outcome was rate of subsequent RNU. Results: Fifteen patients in total underwent PCNSS, 14 were diagnosed with UTUC; benign leiomyoma was proven in one patient and excluded from final analysis. Overall survival at 5 and 10 years was 92.9% and 78.6%, respectively, with disease-specific mortality at 10 years of 7.1% (one patient who developed metastatic carcinoma); 21.4% of patients had recurrent ipsilateral UTUC and all required subsequent RNU for this indication. No patients had seeding of the percutaneous tract. Conclusion: PCNSS for UTUC is a feasible approach to consider in carefully selected patients who agree to intensive follow-up, even for higher grade tumors. Where recurrent UTUC occurs, further management options still exist for disease treatment.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded189    
    Comments [Add]    
    Cited by others 1    

Recommend this journal